| Composition | Voglibose 0.2mg Repaglinide 0.5mg |
|---|---|
| Dosage | TABLET |
| Packing Size | 10×10 |
| Packing | Strip |
At Avecia Healthcare, we believe that professionalism forms the foundation of trust. Our expert team is committed to providing healthcare solutions that meet global standards.
Every product we deliver is a result of thorough research, precision manufacturing, and rigorous quality checks—ensuring consistency in performance and reliability.
With a patient-first approach and a strong ethical foundation, we aim to make a lasting difference in lives by offering care that is both dependable and professionally crafted.
VOGLICOP R 0.2/0.5 Tablets
VOGLICOP R 0.2/0.5 is an effective antidiabetic combination therapy designed to help manage type 2 diabetes. It contains two active ingredients that work synergistically to control blood sugar levels by enhancing insulin action and reducing glucose production in the liver.
The 0.2/0.5 mg dosage is carefully formulated to provide optimal glycemic control while minimizing the risk of side effects. This makes VOGLICOP R 0.2/0.5 suitable for patients who require comprehensive blood sugar management beyond single-drug therapy.
Regular use of VOGLICOP R 0.2/0.5 supports stable blood sugar levels throughout the day, reducing the likelihood of sudden spikes or dips. This is crucial for preventing long-term diabetes complications such as neuropathy, kidney damage, and cardiovascular issues.
Doctors often recommend VOGLICOP R 0.2/0.5 as part of a complete diabetes care regimen, which includes a balanced diet, physical activity, and regular monitoring of blood glucose levels. Patients find it convenient to include in their daily routine, improving adherence and overall effectiveness.
With its reliable formulation and proven efficacy, VOGLICOP R 0.2/0.5 Tablets help individuals manage type 2 diabetes effectively, supporting better health, sustained energy, and improved quality of life.
